'lizbeth
07-15-2013, 08:41 PM
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. (ADAPT; T-DM1)
http://clinicaltrials.gov/show/NCT01745965
The Europeans aren't dragging their feet with TDM1 and early stage breast cancer. Since this is neoadjuvant I am hoping to seeing the data much sooner than in a typical study.
Interesting opportunities.
http://clinicaltrials.gov/show/NCT01745965
The Europeans aren't dragging their feet with TDM1 and early stage breast cancer. Since this is neoadjuvant I am hoping to seeing the data much sooner than in a typical study.
Interesting opportunities.